Autolus Therapeutics/$AUTL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Autolus Therapeutics
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
Ticker
$AUTL
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
649
Website
AUTL Metrics
BasicAdvanced
$671M
-
-$0.89
1.76
-
Price and volume
Market cap
$671M
Beta
1.76
52-week high
$2.70
52-week low
$1.11
Average daily volume
1.7M
Financial strength
Current ratio
9.244
Quick ratio
8.735
Long term debt to equity
83.16
Total debt to equity
83.16
Interest coverage (TTM)
-13.75%
Profitability
EBITDA (TTM)
-259.082
Gross margin (TTM)
-1,620.50%
Net profit margin (TTM)
-2,642.69%
Operating margin (TTM)
-2,966.03%
Effective tax rate (TTM)
-1.60%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-20.27%
Return on equity (TTM)
-49.97%
Valuation
Price to revenue (TTM)
74.433
Price to book
1.81
Price to tangible book (TTM)
1.81
Price to free cash flow (TTM)
-2.363
Free cash flow yield (TTM)
-42.32%
Free cash flow per share (TTM)
-106.65%
Growth
Revenue change (TTM)
-14.16%
Earnings per share change (TTM)
-24.77%
3-year revenue growth (CAGR)
59.35%
3-year earnings per share growth (CAGR)
-21.39%
Bulls say / Bears say
Autolus Therapeutics received FDA approval for AUCATZYL® (obecabtagene autoleucel) in November 2024, marking a significant milestone in its commercialization efforts. (autolus.gcs-web.com)
The company is expanding its pipeline into autoimmune diseases, with the CARLYSLE Phase 1 trial in systemic lupus erythematosus (SLE) expected to present initial data in Q1 2025. (autolus.gcs-web.com)
Autolus has secured a $30 million milestone payment from Blackstone upon FDA approval of AUCATZYL®, bolstering its financial position. (autolus.gcs-web.com)
In Q1 2025, Autolus reported a net loss of $70.2 million, with increased commercialization expenses leading to negative gross margins. (ainvest.com)
The safety profile of AUCATZYL® includes risks such as cytokine release syndrome (CRS) and neurotoxicities, which may impact patient adoption and regulatory scrutiny. (ainvest.com)
Autolus' cash reserves decreased to $516.6 million in Q1 2025, with a notable $20 million delay in U.K. R&D tax credits, raising concerns about cash flow sustainability. (ainvest.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Autolus Therapeutics stock?
Autolus Therapeutics (AUTL) has a market cap of $671M as of July 28, 2025.
What is the P/E ratio for Autolus Therapeutics stock?
The price to earnings (P/E) ratio for Autolus Therapeutics (AUTL) stock is 0 as of July 28, 2025.
Does Autolus Therapeutics stock pay dividends?
No, Autolus Therapeutics (AUTL) stock does not pay dividends to its shareholders as of July 28, 2025.
When is the next Autolus Therapeutics dividend payment date?
Autolus Therapeutics (AUTL) stock does not pay dividends to its shareholders.
What is the beta indicator for Autolus Therapeutics?
Autolus Therapeutics (AUTL) has a beta rating of 1.76. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.